1004294-80-7

Basic information

• Product Name: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
• Synonyms: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one;1-Isoindolinone-6-boronic acid pinacol ester;1H-Isoindol-1-one, 2,3-dihydro-6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;6-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-2,3- dihydro-1H-isoindol-1-one;6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-1-one;2,3-dihydro-6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-;6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-isoindol-1-one;6-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)isoindolin-1-one
• CAS NO: 1004294-80-7
• Molecular Formula: C₁₄H₁₈BNO₃
• Molecular Weight: 259.10862
• Mol File: 1004294-80-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 466.838 °C at 760 mmHg
• Flash Point: 236.136 °C
• Appearance: /
• Density: 1.163 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 13.91±0.20(Predicted)
• CAS DataBase Reference: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one(1004294-80-7)
• EPA Substance Registry System: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one(1004294-80-7)

Safety Data

• Hazardous Substances Data: 1004294-80-7(Hazardous Substances Data)

Usage

General Description

6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one is a chemical compound that features a boron-containing heterocyclic ring. It is commonly used as a reagent in organic synthesis, particularly in the formation of carbon-carbon and carbon-heteroatom bonds. 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one is valued for its ability to selectively mediate various chemical reactions and its high stability, making it useful in the production of pharmaceuticals, agrochemicals, and other fine chemicals. The unique structure of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one also makes it a valuable building block for the creation of complex organic molecules. Furthermore, its potential for use in materials science applications, including in organic optoelectronic devices, has also been investigated.

Upstream product

• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 79669-50-4 methyl 2-methyl-5-bromobenzoate 
• 79670-17-0 methyl 2-bromomethyl-5-bromobenzoate 
• 118-90-1 ortho-methylbenzoic acid 
• 73183-34-3 bis(pinacol)diborane 
• 54811-38-0 5-iodo-2-methylbenzoic?acid 
• 103440-54-6 methyl 5-iodo-2-methylbenzoate 
• 478375-39-2 methyl-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 675109-26-9 6-bromo-1-oxo-2,3-dihydro-1H-isoindole 

Downstream Products

• 1620056-28-1 (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(5-(3-oxoisoindolin-5-yl)-2-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl)ethyl)carbamate 

Relevant articles and documents

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2

Aberrant activation of the MAPK pathway drives cell proliferation in multiple cancers. Inhibitors of BRAF and MEK kinases are approved for the treatment of BRAF mutant melanoma, but resistance frequently emerges, often mediated by increased signaling through ERK1/2. Here, we describe the fragment-based generation of ERK1/2 inhibitors that block catalytic phosphorylation of downstream substrates such as RSK but also modulate phosphorylation of ERK1/2 by MEK without directly inhibiting MEK. X-ray crystallographic and biophysical fragment screening followed by structure-guided optimization and growth from the hinge into a pocket proximal to the C-α helix afforded highly potent ERK1/2 inhibitors with excellent kinome selectivity. In BRAF mutant cells, the lead compound suppresses pRSK and pERK levels and inhibits proliferation at low nanomolar concentrations. The lead exhibits tumor regression upon oral dosing in BRAF mutant xenograft models, providing a promising basis for further optimization toward clinical pERK1/2 modulating ERK1/2 inhibitors.

3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

3- (1H-PYRAZOL-4-YL) PYRIDINEALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.